An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Phase 2

Terminated

• Conditions: Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema
• Interventions: Drug: Inhaled Treprostinil

• Registration Number: NCT02633293
• Lead Sponsor: United Therapeutics

Brief Summary

This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your participation in this study is voluntary and will last until you discontinue from the study or the study ends. The study will continue until each subject reaches the Week 108 visit or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-12-11
• Study First Submitted QC: 2015-12-14
• Study First Posted: 2015-12-17
• Study Start: 2016-09-15
• Primary Completion: 2021-08-01
• Study Completion: 2021-08-01
• Results First Submitted: 2022-07-26
• Status Verified: 2022-11
• Results First Submitted QC: 2022-11-08
• Last Update Submitted: 2022-11-08
• Results First Posted: 2022-12-02
• Last Update Posted: 2022-12-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 243

Inclusion Criteria

1. Subject voluntarily gives informed consent to participate in the study.

2. The subject participated in study RIN-PH-201, remained on study drug, was compliant with RIN-PH-201 study procedures or was enrolled in study RIN-PH-201 at the time that the study was discontinued by the sponsor.

3. Females of reproductive potential must be non-pregnant (as confirmed by a urine pregnancy test at Baseline) and non-lactating, and will:

   • Either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or
   • Use two medically acceptable, highly-effective forms of contraception for the duration of study, and at least 30 days after discontinuing study drug.

4. Males must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.

Exclusion Criteria

1. The subject is pregnant or lactating.
2. The subject was prematurely discontinued from study RIN-PH-201.
3. The subject developed a concurrent illness or condition during the conduct of RIN-PH-201 which, in the opinion of the Investigator, would represent a risk to overall health if they enrolled in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Inhaled Treprostinil	Inhaled Treprostinil	Open-label access

Primary Outcome Measures

Name	Time	Method
Change in Peak 6-Minute Walk Distance (6MWD) From Baseline	Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)	The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for 6 minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Peak exposure 6MWD will occur by conducting 6MWT within 10 to 60 minutes after the most recent dose of study drug dose.

Secondary Outcome Measures

Name	Time	Method
Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline	Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)	The N-terminal pro-BNP (NT-proBNP) serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and each visit through Week 124. Blood for NT-proBNP assessment must be drawn prior to conducting the 6-minute walk test (6MWT).
Change in Percent Predicted Forced Vital Capacity (FVC) From Baseline	Baseline and Weeks 12, 48, and 108	Change in pulmonary function following inhaled treprostinil therapy will be measured by Forced Vital Capacity (FVC), calculated from a Pulmonary Function Test (PFT) performed at Baseline and Weeks 12, 48, and 108.

Trial Locations

Locations (92)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

IMC-Diagnostic & Medical Clinic; 🇺🇸 Mobile, Alabama, United States

Arizona Pulmonary Specialists, Ltd.; 🇺🇸 Phoenix, Arizona, United States

University of Arizona; 🇺🇸 Tucson, Arizona, United States

Cedars-Sinai Medical Center; 🇺🇸 Beverly Hills, California, United States

University of California, San Francisco-Fresno; 🇺🇸 Fresno, California, United States

University of California San Diego; 🇺🇸 La Jolla, California, United States

VA Long Beach Healthcare System; 🇺🇸 Long Beach, California, United States

University of Southern California; 🇺🇸 Los Angeles, California, United States

Department of Veterans Affairs Greater Los Angeles Healthcare System; 🇺🇸 Los Angeles, California, United States

Scroll for more (82 remaining)